Navigation Links
Elbit Medical Imaging Ltd. Announces Adjournment of its Annual General Meeting
Date:10/17/2007

TEL-AVIV, Israel, Oct. 17 /PRNewswire-FirstCall/ -- Elbit Medical Imaging Ltd. (TASE, Nasdaq: EMITF) ("EMI" or the "Company") announced today that the annual general meeting of EMI's shareholders convened on October 17, 2007 and the shareholders present at the meeting resolved to adjourn EMI's annual general meeting to Thursday, November 1, 2007 at 1:00 p.m. (Israel time). The adjourned meeting will be held at EMI's offices at 2 Weitzman Street, 23rd Floor, Tel-Aviv 64239, Israel. The resolution to adjourn the meeting was passed upon a proposal made by the chairman of the meeting in light of recent discussions between EMI and institutional investors shareholders regarding proposals on the agenda of the meeting, and EMI's desire to finalize the discussions before the resolutions are presented to the Company's shareholders.

The agenda for the adjourned meeting, and the record date of the close of business on September 11, 2007 for the shareholders entitled to vote at the meeting, will remain unchanged. For information regarding the agenda at the adjourned meeting, see EMI's proxy statement as submitted on Form 6-K with the U.S. Securities and Exchange Commission and filed with the Israeli Securities Authority, in each case, on September 6, 2007.

The provisions of EMI's proxy statement, dated September 6, 2007 (other than the date and time of the annual general meeting), shall apply also to EMI's adjourned meeting.

About Elbit Medical Imaging Ltd.

EMI is a subsidiary of Europe Israel (M.M.S.) Ltd. EMI's activities are divided into the following principal fields: (i) Initiation, construction, operation, management and sale of shopping and entertainment centers in Israel, Central and Eastern Europe and India; (ii) Hotels ownership, primarily in major European cities, as well as operation, management and sale of same through its subsidiary, Elscint Ltd.; (iii) Investments in the research and development, production and marketing of magnetic
'/>"/>

SOURCE Elbit Medical Imaging Ltd.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...p://www.aronowitzmd.com [Los Angeles cosmetic sur...e in plastic surgery procedures for post bariatric...be necessary for these patients, health and wellne...pecialty of procedures for after weight loss. , ...ust 29, 2008 -- Bariatric surgery improves the hea...
(Date:8/28/2008)...onventional therapy, study found , , THU...a treadmill improves brain function and fitness fo...gh the usual rehabilitation program, a new study f...s have," said study researcher Dr. Andreas Luft, a...tation at the University of Zurich in Switzerland....
(Date:8/28/2008)...l efforts of the Maryland Medicaid contract, HARR...onal medical,management firm, appointed Lenaye Law...r. Dr. Lawyer will oversee all clinical aspects of...nt Valley, Maryland Harrisburg,office., "Dr. Lawy...land," said,Alice Stollenwerk Petrulis, MD, FACP, ...
(Date:8/28/2008)... physical, especially for the impaired, study says...-- A new study says that 13 percent of American se...use. , The University of Chicago researchers s... being taken advantage of financially (3.5 percent... found that seniors with physical impairments were...
Breaking Medicine News(10 mins):Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:Treadmill Workouts Help Stroke Survivors 2Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:13% of Seniors Report Being Mistreated 2
...sandro Remo Zanetti and his colleagues from Instit...ination with Hepatitis B produces the required con... of the patients for long periods//. The researche...inst Hepatitis B vaccination are present in the bl...
... infections are a major cause for hospitalization ...ection are risks for subsequent amputation. Ischem...betes combine to produce tissue necrosis and ulcer...lly polymicrobial in nature. Early recognition of ...
...morphins are highly powerful a tool for pain manag...rived from the opium poppy. It has previously been...erns// of side effects by virtue of their hard-wir...ceptors. Such receptors, known as u-opioids, appea...
... study conducted on factors that predispose to dri...’s tendency to do things like lie, steal or skip s...at a very early age of 12, 13 or 14//. The study ...the issue and is a contradiction to the existing a...
Other Medicine News:Health News:Booster dose not required for Hepatitis B Vaccination 2Health News:The Polymicrobial Nature Of Diabetic Foot Infections 2Health News:Ambiguous Efficacy Of Opioid Drugs In Chronic Inflammatory Joint Pain Relief 2
(Date:8/27/2008)...ght in Parts of Bucks, Delaware, Montgomery,Phila...swire-USNewswire/ -- After encouraging,results fol...epartment of,Environmental Protection will continu...gainst the mosquito-borne West Nile virus., Targe... 8 p.m. and,midnight in portions of Bucks, Delawar...
(Date:8/27/2008)...CADE, melphalan and prednisone arm demonstrated a,...cent complete response -, CAMBRIDGE, Mass., Aug. ... Company today announced the publication of result...A(1) trial in this week,s edition of the,New Engla...ficant survival,benefit and a 30 percent complete ...
(Date:8/27/2008)...st 27 /-, - Oralair(R) Gra...harmacodynamic Study Conducted in an Allergen Chal...ghly positive results of a new study,conducted in ...n Oralair(R) Grasses included 86 adult patients ex...atment durations: 1 week, 1 month,2 and 4 months ...
(Date:8/27/2008)...a, from BLISS-52 trial, expected by mid-2009 - - ... by fall 2009 -, ROCKVILLE, Md., Aug. 27 /PRNewsw...daq: HGSI ) today announced it has completed enro...of two pivotal Phase 3,randomized clinical trials ...tive systemic lupus erythematosus (SLE). Belimumab...
Breaking Medicine Technology:DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 2DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 2Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 1Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 2Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting 1994 3Smokers Cost Medicaid System Nearly 2410 Billion 7170 1Smokers Cost Medicaid System Nearly 2410 Billion 7170 2Smokers Cost Medicaid System Nearly 2410 Billion 7170 3Sigma Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO IEC 17025 and ISO Guide 34 1992 1Sigma Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO IEC 17025 and ISO Guide 34 1992 2Meniscal damage and the development of persistent knee pain 7168 1Meniscal damage and the development of persistent knee pain 7168 2Meniscal damage and the development of persistent knee pain 7168 3
...ults Indicate Bioequivalent Pharmacokinetics With ...X-514, SAN DIEGO, April 25, 2007 /PRNewswire-First...rmaceutical research and,development company focus...es for the treatment of cancer and infectious dise...nical pharmacokinetic,testing of ANX-514 (docetaxe...
...SEL, Switzerland, April 25, 2007 - Basilea Pharmac...udy results showing that,patients with severe chro... alitretinoin. In two previous randomized clinical... treating severe,chronic hand eczema in patients r...l demonstrated that patients responsive to initial...
Other Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box.
Hydrodissection / Aspiration Cannula, 25 g. Straight with U-tip. U-shaped tip allows aspiration and irrigation at the 12 o'clock position. Overall length 18 mm. 5/box.
Silicone Capsule Polisher, 27 g. Silicon tip to provide squeegee effect. Overall length 22 mm. 5/box.
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box.
Medicine Products: